nach oben

Current Pulmonology Reports

Erschienen in:

11.08.2018 | Lungs Transplant (R Bag, Section Editor)

Rising to the Challenge of Unmet Need: Expanding the Lung Donor Pool

verfasst von: Aadil Ali, Shaf Keshavjee, Marcelo Cypel

Erschienen in: Current Pulmonology Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There is a shortage of lungs available to meet the needs of patient who require lung transplantation. Ex vivo lung perfusion (EVLP) has allowed for the assessment and reconditioning of extended criteria and high-risk donor lungs, allowing for an increased volume of lung transplants. Recently, an invested interest in the utilization donation after cardiac death (DCD) donors has surfaced, in which EVLP has played an important role.

Recent Findings

Clinical studies have shown that EVLP can recondition donor lungs that initially would be unacceptable for transplantation. In a recent study, the intervention of EVLP was also shown to extend the window of total organ preservation time. Preclinical studies have shown promising results for EVLP to serve as a therapeutic platform to modulate inflammation, reduce edema, and treat infections and aspiration injuries. In addition, studies have shown the potential to recondition lungs of donation after cardiac death donors which suffer from additional injury in comparison to donation after brain death donors.

Summary

EVLP is dynamic platform that can serve to treat and array of issues prior to transplantation. Indeed, the investigation of these therapeutic arsenals will soon allow physicians to expand the donor organ pool and improve transplantation outcomes.

Punch JD, Hayes DH, Laporte FB, McBride V, Seely MS. Organ donation and utilization in the United States, 1996-2005. Am J Transplant. 2007;7:1327–38.CrossRefPubMed

de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003;167:490–511.CrossRefPubMed

Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187:527–34.

De Meester J, Smits JMA, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Hear Lung Transplant. 2001;20:518–24.CrossRef

Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:659–64.CrossRefPubMedPubMedCentral

Titman a RC a, Bonser RS, Banner NR, Sharples LD. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant. 2009;9:1640–9.CrossRefPubMed

Valapour M, Paulson K, Smith JM, Hertz MI, M a S, Heubner BM, et al. OPTN/SRTR 2011 Annual Data Report: lung. Am J Transplant 13 Suppl. 2013;1:149–77.

Yusen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart–lung transplant report—2016; focus theme: primary diagnostic indications for transplant. J Hear Lung Transplant. 2016;35:1170–84.

Erasmus ME, Fernhout MH, Elstrodt JM, Rakhorst G. Normothermic ex vivo lung perfusion of non-heart-beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation. Transpl Int. 2006;19:589–93.CrossRefPubMed

10.

Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, et al. Technique for prolonged Normothermic ex vivo lung perfusion. J Hear Lung Transplant. 2008;27:1319–25.

11.

Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:1431–40.

12.

Cypel M, Yeung JC, Machuca T, Chen M, Singer LG, Yasufuku K, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg. 2012;144:1200–7. https://doi.org/10.1016/j.jtcvs.2012.08.009.

13.

Machuca TN, Mercier O, Collaud S, Tikkanen J, Krueger T, Yeung JC, et al. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion. Am J Transplant. 2015;15:993–1002.

14.

Tikkanen JM, Cypel M, Machuca TN, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Hear Lung Transplant. 2014;34:1–10.

15.

Aigner C, Slama A, Hötzenecker K, Scheed A, Urbanek B, Schmid W, et al. Clinical ex vivo lung perfusion - pushing the limits. Am J Transplant. 2012;12:1839–47.

16.

Boffini M, Ricci D, Bonato R, Fanelli V, Attisani M, Ribezzo M, et al. Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion. Eur J Cardiothorac Surg. 2014;46:789–93.

17.

Sage E, Mussot S, Trebbia G, Puyo P, Stern M, Dartevelle P, et al. Lung transplantation from initially rejected donors after ex vivo lung reconditioning: the French experience. Eur J Cardio-thoracic Surg. 2014;46:794–9.

18.

Zych B, Popov AF, Stavri G, Bashford A, Bahrami T, Amrani M, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Hear Lung Transplant. 2012;31:274–81.

19.

•• Yeung JC, Krueger T, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med. 2016;2600:1–6. Publication showing that EVLP can increase total safe preservation times.

20.

Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001;357:825–9.CrossRefPubMed

21.

Steen S, Ingemansson R, Eriksson L, Pierre L, Algotsson L, Wierup P, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg. 2007;83:2191–4.

22.

Iversen Henriksen IS, Møller-Sørensen H, Holdflod Møller C, Zemtsovski M, Christian Nilsson J, Tobias Seidelin C, et al. First Danish experience with ex vivo lung perfusion of donor lungs before transplantation. Dan Med J. 2014;61:A4809.

23.

Wallinder A, Ricksten SE, Silverborn M, Hansson C, Riisec GC, Liden H, et al. Early results in transplantation of initially rejected donor lungs after ex vivo lung perfusion: a case-control study. Eur J Cardio-Thoracic Surg. 2014;45:40–5.

24.

Warnecke G, Moradiellos J, Tudorache I, Kühn C, Avsar M, Wiegmann B, et al. Normothermic perfusion of donor lungs for preservation and assessment with the organ care system lung before bilateral transplantation: a pilot study of 12 patients. Lancet. 2012;380:1851–8.

25.

Ceulemans LJ, Monbaliu D, Verslype C, van der Merwe S, Laleman W, Vos R, et al. Combined liver and lung transplantation with extended normothermic lung preservation in a patient with end-stage emphysema complicated by drug-induced acute liver failure. Am J Transplant. 2014;14:2412–6.

26.

Mohite PN, Sabashnikov A, García Sáez D, Pates B, Zeriouh M, De Robertis F, et al. Utilization of the organ care system lung for the assessment of lungs from a donor after cardiac death (DCD) before bilateral transplantation. Perfus (United Kingdom). 2015;30:427–30.

27.

Bharat A, Narayanan K, Street T, Fields RC, Steward N, Aloush A, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation. 2007;83:150–8.

28.

Kaneda H, Waddell TK, De Perrot M, Bai XH, Gutierrez C, Arenovich T, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant. 2006;6:544–51.

29.

De Perrot M, Sekine Y, Fischer S, Waddell TK, Mcrae K, Liu M, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med. 2002;165:211–5.

30.

Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009;1:4ra9.CrossRefPubMed

31.

Moore KW, De Waal Malefyt R, Coffman RL, O ‘garra A. Interleukin-10 and the Interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.CrossRefPubMed

32.

Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2(8):8.CrossRef

33.

Mordant P, Nakajima D, Kalaf R, Iskender I, Maahs L, Behrens P, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation. J Hear Lung Transplant. 2016;35:1245–54.

34.

Mordant P, Nakajima D, Kalaf R, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration of IL-8 during ex vivo perfusion of donor lungs after 18h preservation. J Hear Lung Transplant. 2016:1–10.

35.

Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. Coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106:16357–62.CrossRefPubMedPubMedCentral

36.

Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344:665–71.CrossRefPubMed

37.

Inci I, Ampollini L, Arni S, Jungraithmayr W, Inci D, Hillinger S, et al. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. J Hear Lung Transplant. 2008;27:1229–36.

38.

Meers CM, Tsagkaropoulos S, Wauters S, Verbeken E, Vanaudenaerde B, Scheers H, et al. A model of ex vivo perfusion of porcine donor lungs injured by gastric aspiration: a step towards pretransplant reconditioning. J Surg Res. 2011;170:e159–67.

39.

• Khalife-Hocquemiller T, Sage E, Dorfmuller P, Mussot S, Le Houerou D, Eddahibi S, et al. Exogenous surfactant attenuates lung injury from gastric-acid aspiration during ex vivo reconditioning in pigs. Transplantation. 2014;97:413–8. Publication showing surfactant therapy can attenuate artificial aspiration-induced injury during EVLP.

40.

• Nakajima D, Liu M, Ohsumi A, Kalaf R, Iskender I, Hsin M, et al. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration-induced donor lung injury. J Hear Lung Transplant. 2017;36:577–85. Publication showing surfactant therapy can attenuate artificial aspiration-induced injury during EVLP.

41.

Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009;6:94–100.CrossRefPubMed

42.

Andreasson A, Karamanou DM, Perry JD, Perry A, Ӧzalp F, Butt T, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Hear Lung Transplant. 2014;33:910–6.

43.

• Nakajima D, Cypel M, Bonato R, Machuca TN, Iskender I, Hashimoto K, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016;16:1229–37. Publication showing succesful treatment of human donor lungs using high dose antibiotics

44.

•• Zinne N, Krueger M, Hoeltig D, et al. Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: A pilot study in pigs. PLoS One. 2018; https://doi.org/10.1371/journal.pone.0193168. First animal study demonstrating EVLP followed by autotransplantation.

45.

M a M, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev. 2002;82:569–600.CrossRef

46.

Mutlu GM, Dumasius V, Burhop J, McShane P, Meng FJ, Welch L, et al. Upregulation of alveolar epithelial active Na+ transport is dependent on beta2-adrenergic receptor signaling. Circ Res. 2004;94:1091–100.

47.

Lasnier JM, Wangensteen OD, Schmitz LS, Gross CR, Ingbar DH. Terbutaline stimulates alveolar fluid resorption in hyperoxic lung injury. J Appl Physiol. 1996;81:1723–9.CrossRefPubMed

48.

Frank JA, Briot R, Lee JW, Ishizaka A, Uchida T, Matthay MA. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293:L52–9.CrossRefPubMedPubMedCentral

49.

Valenza F, Rosso L, Coppola S, Froio S, Colombo J, Dossi R, et al. β-Adrenergic agonist infusion during extracorporeal lung perfusion: effects on glucose concentration in the perfusion fluid and on lung function. J Hear Lung Transplant. 2012;31:524–30.

50.

Valenza F, Rosso L, Pizzocri M, Salice V, Umbrello M, Conte G, et al. The consumption of glucose during ex vivo lung perfusion correlates with lung edema. Transplant Proc. 2011;43:993–6.

51.

Kondo T, Chen F, Ohsumi A, Hijiya K, Motoyama H, Sowa T, et al. β2-Adrenoreceptor agonist inhalation during ex vivo lung perfusion attenuates lung injury. Ann Thorac Surg. 2015;100:480–6.

52.

Oto T, Rabinov M, Griffiths AP, Whitford H, Levvey BJ, Esmore DS, Williams TJ, Snell GI (2005) Unexpected donor pulmonary embolism affects early outcomes after lung transplantation : A major mechanism of primary graft failure ? 1–9.

53.

Machuca TN, Hsin MK, Ott HC, Chen M, Hwang DM, Cypel M, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med. 2013;188:878–80.

54.

Luc JGY, Bozso SJ, Freed DH, Nagendran J. Successful repair of donation after circulatory death lungs with large pulmonary embolus using the lung organ care system for ex vivo thrombolysis and subsequent clinical transplantation. Transplantation. 2015;99:e1–2.CrossRefPubMed

55.

Inci I, Yamada Y, Hillinger S, Jungraithmayr W, Trinkwitz M, Weder W. Successful lung transplantation after donor lung reconditioning with urokinase in ex vivo lung perfusion system. Ann Thorac Surg. 2014;98:1837–8.CrossRefPubMed

56.

Snell GI, Griffiths A, Levvey BJ, Oto T. Availability of lungs for transplantation: exploring the real potential of the donor pool. J Hear Lung Transplant. 2008;27:662–7.CrossRef

57.

Reeb J, Keshavjee S, Cypel M. Expanding the lung donor pool: advancements and emerging pathways. Curr Opin Organ Transpl. 2015;20:498–505.CrossRef

58.

Cypel M, Levvey B, Van Raemdonck D, et al. International Society for Heart and Lung Transplantation donation after circulatory death registry report. J Hear lung Transplant. 2015;34:1278–82.CrossRef

59.

Mooney JJ, Hedlin H, Mohabir PK, Vazquez R, Nguyen J, Ha R, et al. Lung quality and utilization in controlled donation after circulatory determination of death within the United States. Am J Transplant. 2016;16:1207–15.

60.

Gomez-De-Antonio D, Campo-Caaveral JL, Crowley S, Valdivia D, Cordoba M, Moradiellos J, et al. Clinical lung transplantation from uncontrolled nonheart-beating donors revisited. J Hear Lung Transplant. 2012;31:349–53.

61.

Levvey BJ, Harkess M, Hopkins P, Chambers D, Merry C, Glanville AR, et al. Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaborative. Am J Transpl. 2012;12:2406–13.

62.

Van De Wauwer C, Verschuuren EAM, van der Bij W, Nossent GD, Erasmus ME. The use of non-heart-beating lung donors category III can increase the donor pool. Eur J Cardio-thoracic Surg. 2011;39:e175–80.CrossRef

63.

De Vleeschauwer SI, Wauters S, Dupont LJ, Verleden SE, Willems-Widyastuti A, Vanaudenaerde BM, et al. Medium-term outcome after lung transplantation is comparable between brain-dead and cardiac-dead donors. J Hear Lung Transplant. 2011;30:975–81.

64.

Puri V, Scavuzzo M, Guthrie T, Hachem R, Krupnick AS, Kreisel D, et al. Lung transplantation and donation after cardiac death: a single center experience. In: Ann Thorac Surg 88:1609–14–5, vol. 88; 2009. p. 1609–15.

65.

De Vleeschauwer S, Van Raemdonck D, Vanaudenaerde B, et al. Early outcome after lung transplantation from non-heart-beating donors is comparable to heart-beating donors. J Hear Lung Transplant. 2009;28:380–7.CrossRef

66.

Cypel M, Sato M, Yildirim E, Karolak W, Chen F, Yeung J, et al. Initial experience with lung donation after Cardiocirculatory death in Canada. J Hear Lung Transplant. 2009;28:753–8.

67.

Mason DP, Thuita L, Alster JM, Murthy SC, Budev MM, Mehta AC, et al. Should lung transplantation be performed using donation after cardiac death? The United States experience. J Thorac Cardiovasc Surg. 2008;136:1061–6.

68.

Zych B, Popov AF, Amrani M, Bahrami T, Redmond KC, Krueger H, et al. Lungs from donation after circulatory death donors: an alternative source to brain-dead donors? Midterm results at a single institution. Eur J Cardio-thoracic Surg. 2012;42:542–9.

69.

de Antonio DG, Marcos R, Laporta R, Mora G, García-Gallo C, Gámez P, et al. Results of clinical lung transplant from uncontrolled non-heart-beating donors. J Hear Lung Transplant. 2007;26:529–34.

70.

Hernadez-Alejandro R, Wall W, Jevnikar A, Luke P, Sharpe M, Russell D, et al. Organ donation after cardiac death: donor and recipient outcomes after the first three years of the Ontario experience. Can J Anaesth. 2011;58:599–605.

71.

Martens A, Montoli M, Faggi G, Katz I, Pype J, Vanaudenaerde BM, et al. Argon and xenon ventilation during prolonged ex vivo lung perfusion. J Surg Res. 2016;201:44–52.

72.

Kalaf-Mussi R, Lee J, Nakajima D, Chen M, Maahs L, Coutinho R, et al. Ex-vivo therapeutic use of carbon monoxide (CO) to improve donor lungs for transplantation. J Hear Lung Transplant. 2015;34:S92–3.

73.

Haam S, Lee S, Paik HC, Park MS, Song JH, Lim BJ, et al. The effects of hydrogen gas inhalation during ex vivo lung perfusion on donor lungs obtained after cardiac death. Eur J Cardio-thoracic Surg. 2015;48:542–7.

74.

Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, et al. Steroids can reduce warm ischemic reperfusion injury in a porcine DCD model with EVLP evaluation. Transpl Int. 2016;29:1237–46.

75.

Inci I, Arni S, Acevedo C, Jungraithmayr W, Inci D, Vogt P, et al. Surfactant alterations following donation after cardiac death donor lungs. Transpl Int. 2011;24:78–84.

76.

Inci I, Hillinger S, Arni S, Kaplan T, Inci D, Weder W. Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an ex vivo lung perfusion system followed by transplantation. J Surg Res. 2013;184:1143–9.CrossRefPubMed

77.

Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest. 2006;116:2173–82.

78.

Huerter ME, Sharma AK, Zhao Y, Charles EJ, Kron IL, Laubach VE. Attenuation of pulmonary ischemia-reperfusion injury by adenosine A2BReceptor antagonism. Ann Thorac Surg. 2016;102:385–93.CrossRefPubMedPubMedCentral

79.

Francioli C, Wang X, Parapanov R, Abdelnour E. Pyrrolidine dithiocarbamate administered during ex-vivo lung perfusion promotes rehabilitation of injured donor rat lungs obtained after prolonged warm ischemia. PLoS One. 2017;12:1–15.CrossRef

Titel: Rising to the Challenge of Unmet Need: Expanding the Lung Donor Pool
verfasst von: Aadil Ali
Shaf Keshavjee
Marcelo Cypel
Publikationsdatum: 11.08.2018
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 3/2018
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-018-0205-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rising to the Challenge of Unmet Need: Expanding the Lung Donor Pool

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics

Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy

It's What’s Inside that Counts: Body Composition and Lung Transplantation

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin